🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts

EntrackrEntrackr · 20d ago
PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts
Medial

Snippets PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts Bengaluru-based biopharma company PlasmaGen Biosciences has raised Rs 150 crore led by ViNS Bioproducts along with participation from high-net-worth individuals, family offices, pharma entrepreneurs, and existing investors. The startup is backed by Eight Road Ventures secured the funding at a valuation of over Rs 1,500 crore. PlasmaGen has mopped up over Rs 600 crore in funding to date from Fidelity's FIL Capital Investments, Eight Roads Ventures, F-Prime Capital, and others. The proceeds will be used to scale international operations, expand the product portfolio, and strengthen manufacturing and leadership capabilities, PlasmaGen Biosciences said in a press release. Founded in 2010, PlasmaGen Biosciences focuses on producing and marketing plasma-derived therapies like Immunoglobulin, Albumin, and clotting factors to bridge India's demand-supply gap for these critical medicines, operating a modern fractionation plant in Kolar, Karnataka, and serving neurology, hematology, and critical care, aiming for self-reliance in plasma products. According to PlasmaGen, it has identified distribution partners in key export geographies and is in the process of securing regulatory approvals to begin international sales. India continues to remain a key market for the firm, which is expanding its services across hospitals and physicians through a cold-chain-backed distribution network. PlasmaGen says that it began commercial operations in 2024 at its plasma fractionation facility in Kolar, near Bengaluru. The company asserts that the setup is among only five such facilities in the country and claims that it is the first pure-play plasma biopharma player, has reported strong revenue growth since launch of operations at Kolar and is now preparing to enter overseas markets.

Exclusive: Wint Wealth to raise Series B at Rs 700 Cr valuation

EntrackrEntrackr · 18d ago
Exclusive: Wint Wealth to raise Series B at Rs 700 Cr valuation
Medial

Exclusive: Wint Wealth to raise Series B at Rs 700 Cr valuation Wint Wealth is raising Rs 120 crore (approximately $13.3 million) in its Series B funding round led by Vertex Ventures. This marks the Bengaluru-based startup’s first major fundraise in over three and a half years. Wint Wealth’s board has passed a special resolution to issue 94,047 Series B compulsory convertible preference shares at an issue price of Rs 12,804 each to raise Rs 120 crore or $13.3 million, according to the filings sourced from the Registrar of Companies. Vertex Ventures will lead the round with an investment of Rs 77.52 crore, while Unitary Fund, Eight Roads Ventures, and 3one4 Capital will infuse Rs 18.7 crore, Rs 13 crore, and Rs 8.16 crore, respectively. Zerodha’s incubation arm, Rainmatter, will also participate in the Series B with a Rs 3 crore investment. As per filings, the company plans to utilise the proceeds towards capital expenditure, marketing, and general corporate purposes. Based on Entrackr’s estimates, the wealth management startup is raising fresh capital at a post-money valuation of around Rs 707 crore (nearly $80 million). The company may raise additional capital as part of the Series B round, which could lead to changes in its valuation and shareholding structure. Post this round, Vertex Ventures will hold a 10.96% stake in Wint Wealth, while 3one4 Capital, Unitary Fund, Rainmatter, and ERVI Technology, an arm of Eight Roads Ventures, will own 8.54%, 8.32%, 2.55%, and 1.84%, respectively, according to the filings. Wint Wealth is yet to file its FY25 numbers. In FY24, the company posted Rs 17.2 crore operating revenue with a loss of Rs 18 crore.

Toothsi parent MakeO set to raise funds at 50% valuation cut

EntrackrEntrackr · 8m ago
Toothsi parent MakeO set to raise funds at 50% valuation cut
Medial

MakeO, the parent of dental tech startup Toothsi and skincare brand Skinnsi, to secure Rs 54.7 crore (around $6.43 million) fresh funding round led by existing investors Siddharth Shah (Co-founder & CEO of Pharmeasy) with the participation of Mahendra Shah. Existing backers including 360 One, Eight Roads Ventures, Paramark Ventures, Ashish Kacholia and others also joined the round. The board at makeO passed a special resolution to approve the issuance of 5,80,072 CCPS at an issue price of Rs 943.7 each to raise the sum, which is around 57% lower than its previous round of funding, its regulatory filing accessed from the Registrar of Companies (RoC) shows. Siddharth Shah will lead the Rs 20 crore investment round, followed by Mahendra Shah and 360 One, who will each contribute Rs 10 crore. Paramark Ventures and Eight Roads Ventures will invest Rs 4.35 crore each, while the remaining amount will be covered by Ashish Kacholia, Siddhant Partners, and R.B.A Finance & Investment Co. The company has already received Rs 10 crore from Mahendra Shah, with the remaining amount expected to follow soon. The filings further noted that the company plans to utilize the fresh capital for general corporate purposes. Founded in 2018 by Arpi Mehta Shah, Pravin Shetty, Manjul Jain, and Anirudh Kal, MakeO began as the aligner brand Toothsi. In September 2022, it merged its flagship brands, Toothsi and Skinnsi to launch MakeO, offering dental, skin, and hair treatment solutions under a single platform. The Anushka Sharma and Virat Kohli-backed company will be valued at Rs 1,055 crore ($124 million), marking a valuation cut of over 50% compared to its previous $16 million funding round in January 2024 led by 360 One, which valued the company at around Rs 2,231 crore or $ 265 million. According to startup data intelligence platform TheKredible, the Mumbai-based company has raised over $90 million to date including $40 million raised in Series C round in May 2022. While the company is yet to disclose its FY25 figures, its operating revenue in FY24 saw a marginal increase to Rs 179 crore. However, it reduced its losses by 32% to Rs 150 crore during the same period.

Download the medial app to read full posts, comements and news.